Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases

Biological Psychiatry

Volumn 45, Issue 6, 1999, Pages 680-686

  Szeszko, Philip R ^a   Bilder, Robert M ^a,b   Dunlop, Judy A ^a   Walder, Deborah J ^c   Lieberman, Jeffrey A ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b Center for Advanced Brain Imaging   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine agonist; Methylphenidate; Redundancy bias; Schizophrenia; Word production

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; METHYLPHENIDATE;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; FEMALE; FRONTAL LOBE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; VERBAL BEHAVIOR;

ADULT; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; METHYLPHENIDATE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SPEECH; VERBAL BEHAVIOR;

EID: 0033559046     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00258-3     Document Type: Article

References (48)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms in Schizophrenia. 1983;University of Iowa, Iowa City, IA.
2. Andreasen N.C., Arndt S., Alliger R., Miller D., Flaum M. Symptoms of schizophrenia Methods, meanings and mechanisms . Arch Gen Psychiatry. 52:1995;341-351.
3. Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative and positive symptoms in schizophrenia. Psychopharmacology. 72:1980;17-19.
4. Barr W.B., Bilder R.M., Goldberg E., Kaplan E., Mukherjee S. The neuropsychology of schizophrenic speech. J Commun Disord. 22:1989;327-349.
5. Benton A, Hamsher K deS (1978): Multilingual Aphasia Examination. Iowa City: University of Iowa.
6. Bilder R.M. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry. 42:1997;255-264.
7. Bilder R.M., Goldberg E. Motor perseverations in schizophrenia. Arch Clin Neuropsychol. 2:1987;195-214.
8. Bilder R.M., Lieberman J.A., Kim Y. Neuropsychological responses to stimulant challenge in schizophrenia. [Ab] Schizophr Res. 2:1989;52.
9. Bilder R.M., Lieberman J.A., Kim Y., Alvir J.A., Reiter G. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiat Neuropsychol Behav Neurol. 5:1992;262-271.
10. Bilder R.M., Mukherhjee S., Rieder R.O., Pandurangi A.K. Symptomatic and neuropsychological components of defect states. Schizophr Bull. 11:1985;409-419.
11. Bilder R.M., Szeszko P.S. Structural neuroimaging and neuropsychological impairments. Pantellis C., Nelson H.E., Barnes T.R.E. The Neuropsychology of Schizophrenia. 1996;279-298 Wiley, Sussex UK.
12. Braff D.L., Heaton R.K., Kuck J., et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry. 48:1991;891-898.
13. Cohen J., Servan-Schreiber D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr Bull. 19:1993;85-104.
14. Crawford J.R., Obonsawin M.C., Bremner M. Frontal lobe impairment in schizophrenia Relationship to intellectual functioning . Psychol Med. 23:1993;787-790.
15. Daniel D.G., Weinberger D.R., Jones D.W., et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
16. Davis K., Kahn R., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
17. Early T.S., Posner M.I., Reiman E., Raichle M.E. Hyperactivity of the left striato-pallidal projection. Part I: Lower level theory . Psychiatr Dev. 2:1989;85-108.
18. Early T.S., Posner M.I., Reiman E., Raichle M.E. Left striato-pallidal hyperactivity in schizophrenia Part II Phenomenology and thought disorder . Psychiatr Dev. 2:1989;109-121.
19. Frith C.D., Done D.J. Stereotyped responding by schizophrenic patients on a two choice guessing task. Psychol Med. 13:1983;779-786.
20. Fuster J. The Prefrontal Cortex. 1989;Raven Press, New York.
21. Ferris R., Tang F., Maxwell R. A comparison of the capabilities of isomers of amphetamine, deoxyperadrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus, and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol. 181:1972;407-416.
22. Goldberg T.E., Bigelow L.B., Weinberger D.R., Daniel D.G., Kleinman J.E. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 148:1991;78-84.
23. Grube B, Bilder RM, Goldman RS, Lieberman JA (in press). Meta-analysis of symptom factors in schizophrenia. Schizophr Res.
24. Gruzelier J.H., Seymour K., Wilson L., Jolley A., Hirsch S.R. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry. 45:1988;623-629.
25. Kelley A.E., Lang C.G., Gauthier A.M. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology. 95:1988;556-559.
26. Kolb B., Whishaw I.Q. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J Nerv Mental Dis. 171:1983;435-443.
27. Liddle P.F. The symptoms of chronic schizophrenia A re-examination of the positive-negative dichotomy . Br J Psychiatry. 151:1987;145-151.
28. Lieberman J.A., Jody D., Alvir J.M.J., et al. Brain morphology, dopamine and eye tracking abnormalities in first episode schizophrenia Prevalence and clinical correlates . Arch Gen Psychiatry. 50:1993;357-368.
29. Lieberman J.A., Jody D., Geisler S., et al. Time course and biological correlates of treatment response in first episode schizophrenia. Arch Gen Psychiatry. 50:1993;369-376.
30. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
31. Lieberman J.L., Kane J.M., Gadaleta D., Brenner R., Lesser M.S., Kinon B.K. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 141:1984;633-638.
32. Lieberman J.A., Alvir J.M.J., Woerner M., et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull. 18:1992;351-371.
33. Lieberman J.A., Sheitman B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia Deficits in neuronal regulation and plasticity . Neuropsychopharmacology. 17:1997;205-229.
34. Lyon M., Robbins T.W. The action of central nervous system stimulant drugs A general theory concerning amphetamine effects . Essman W., Valzelli L. Current Developments in Psychopharmacology. 1975;79-163 Spectrum, New York.
35. Lyon N., Mejsholm B., Lyon M. Stereotyped responding by schizophrenic out-patients Cross cultural confirmation of perseverative switching on a two-choice task . J Psychiat Res. 10:1986;137-150.
36. Matthysee S. Antipsychotic drug actions A clue to the neuropathology of schizophrenia? Fed Proc. 32:1973;200-205.
37. Pliskin N.H., Raz N., Kirch D., Weinberger D. The effects of neuroleptic medication on selected cognitive functions in schizophrenia. [Ab] J Clin Exper Neuropsychol. 11:1989;82.
38. Pribram K.H., McGuinness D. Arousal, activation, and effort in the control of attention. Psychol Rev. 82:1975;116-149.
39. Randrup A., Munkvad I. Biochemical, anatomical and psychological investigations of stereotyped behavior induced by amphetamines. Costa E., Garattini S. International Symposium on Amphetamines and Related Compounds. 1970;695-713 Raven Press, New York.
40. Randrup A., Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia. 11:1967;300-310.
41. Sawaguchi T., Goldman-Rakic P. D1 dopamine receptors in prefrontal cortex Involvement in working memory . Science. 251:1991;947-950.
42. Seeman P. Anti-schizophrenic drugs Membrane receptor sites of action . Biochem Pharmacol. 26:1977;1741-1748.
43. Simpson A., Lee B., Zoubok B., Gardos G. A rating scale for tardive dyskinesia. Psychopharm. 64:1979;171-179.
44. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand. 212:(suppl):1970;1-58.
45. Spitzer R.L., Endicott J. Schedule for Affective Disorders and Schizophrenia-Change Version. 3rd ed. 1978;New York State Psychiatric Institute, New York.
46. Tucker D.M., Williamson P.A. Asymmetric neural control systems in human self-regulation. Psychol Rev. 91:(2):1984;185-215.
47. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats Modulation by dopamine . J Neurosci. 16:1996;373-379.
48. Yurgelun-Todd D.A., Waternaux C.M., Cohen B.M., et al. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry. 153:1996;200-205.